TY - JOUR
T1 - Investigating Compensatory Brain Activity in Older Adults with Subjective Cognitive Decline
AU - Krebs, Christine
AU - Brill, Esther
AU - Minkova, Lora
AU - Federspiel, Andrea
AU - Kellner-Weldon, Frauke
AU - Wyss, Patric
AU - Teunissen, Charlotte E.
AU - van Harten, Argonde C.
AU - Seydell-Greenwald, Anna
AU - Klink, Katharina
AU - Züst, Marc A.
AU - Brem, Anna-Katharine
AU - Klöppel, Stefan
N1 - Funding Information: This research was funded by the Swiss National Science Foundation (SNSF; grant number 32003B_189240). Publisher Copyright: © 2023 - The authors. Published by IOS Press.
PY - 2023/5/2
Y1 - 2023/5/2
N2 - BACKGROUND: Preclinical Alzheimer's disease (AD) is one possible cause of subjective cognitive decline (SCD). Normal task performance despite ongoing neurodegeneration is typically considered as neuronal compensation, which is reflected by greater neuronal activity. Compensatory brain activity has been observed in frontal as well as parietal regions in SCD, but data are scarce, especially outside the memory domain. OBJECTIVE: To investigate potential compensatory activity in SCD. Such compensatory activity is particularly expected in participants where blood-based biomarkers indicated amyloid positivity as this implies preclinical AD. METHODS: 52 participants with SCD (mean age: 71.00±5.70) underwent structural and functional neuroimaging (fMRI), targeting episodic memory and spatial abilities, and a neuropsychological assessment. The estimation of amyloid positivity was based on plasma amyloid-β and phosphorylated tau (pTau181) measures. RESULTS: Our fMRI analyses of the spatial abilities task did not indicate compensation, with only three voxels exceeding an uncorrected threshold at p < 0.001. This finding was not replicated in a subset of 23 biomarker positive individuals. CONCLUSION: Our results do not provide conclusive evidence for compensatory brain activity in SCD. It is possible that neuronal compensation does not manifest at such an early stage as SCD. Alternatively, it is possible that our sample size was too small or that compensatory activity may be too heterogeneous to be detected by group-level statistics. Interventions based on the individual fMRI signal should therefore be explored.
AB - BACKGROUND: Preclinical Alzheimer's disease (AD) is one possible cause of subjective cognitive decline (SCD). Normal task performance despite ongoing neurodegeneration is typically considered as neuronal compensation, which is reflected by greater neuronal activity. Compensatory brain activity has been observed in frontal as well as parietal regions in SCD, but data are scarce, especially outside the memory domain. OBJECTIVE: To investigate potential compensatory activity in SCD. Such compensatory activity is particularly expected in participants where blood-based biomarkers indicated amyloid positivity as this implies preclinical AD. METHODS: 52 participants with SCD (mean age: 71.00±5.70) underwent structural and functional neuroimaging (fMRI), targeting episodic memory and spatial abilities, and a neuropsychological assessment. The estimation of amyloid positivity was based on plasma amyloid-β and phosphorylated tau (pTau181) measures. RESULTS: Our fMRI analyses of the spatial abilities task did not indicate compensation, with only three voxels exceeding an uncorrected threshold at p < 0.001. This finding was not replicated in a subset of 23 biomarker positive individuals. CONCLUSION: Our results do not provide conclusive evidence for compensatory brain activity in SCD. It is possible that neuronal compensation does not manifest at such an early stage as SCD. Alternatively, it is possible that our sample size was too small or that compensatory activity may be too heterogeneous to be detected by group-level statistics. Interventions based on the individual fMRI signal should therefore be explored.
KW - Blood-based biomarkers
KW - episodic memory
KW - functional MRI
KW - neuronal compensation
KW - spatial abilities
KW - subjective cognitive decline
UR - http://www.scopus.com/inward/record.url?scp=85159552693&partnerID=8YFLogxK
U2 - https://doi.org/10.3233/JAD-221001
DO - https://doi.org/10.3233/JAD-221001
M3 - Article
C2 - 36970895
SN - 1387-2877
VL - 93
SP - 107
EP - 124
JO - Journal of Alzheimer s disease
JF - Journal of Alzheimer s disease
IS - 1
ER -